{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:14:56Z","timestamp":1761167696031,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone &amp; IGF Research"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.ghir.2013.04.002","type":"journal-article","created":{"date-parts":[[2013,5,4]],"date-time":"2013-05-04T11:50:17Z","timestamp":1367668217000},"page":"114-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pegvisomant bioavailability of single 30 mg\/mL subcutaneous injection compared to two 15 mg\/mL subcutaneous injections: A pharmacokinetic, safety and tolerability study"],"prefix":"10.1016","volume":"23","author":[{"given":"Juif","family":"Jen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"LaBadie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope H.","family":"Crownover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana H.","family":"Hey-Hadavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9295","key":"10.1016\/j.ghir.2013.04.002_bb0005","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ghir.2013.04.002_bb0010","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"16","key":"10.1016\/j.ghir.2013.04.002_bb0015","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ghir.2013.04.002_bb0020","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1158\/1078-0432.CCR-06-1910","article-title":"Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy","volume":"13","author":"Yin","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ghir.2013.04.002_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(87)90090-8","article-title":"Metabolism of protein anticancer agents","volume":"34","author":"Bocci","year":"1987","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ghir.2013.04.002_bb0040","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/er.2001-0022","article-title":"Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly","volume":"23","author":"Kopchick","year":"2002","journal-title":"Endocr. Rev."},{"issue":"9","key":"10.1016\/j.ghir.2013.04.002_bb0045","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1210\/jc.2003-031781","article-title":"Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization","volume":"89","author":"Maamra","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ghir.2013.04.002_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1210\/edrv-12-3-189","article-title":"Human growth hormone replacement therapy: pharmacological and clinical aspects","volume":"12","author":"J\u00f8rgensen","year":"1991","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ghir.2013.04.002_bb0055","first-page":"213","article-title":"The absorption kinetics of subcutaneously administered growth hormone: influence of injection volume","volume":"3","author":"J\u00f8rgensen","year":"1989","journal-title":"J. Pediatr. Endocrinol"},{"issue":"5","key":"10.1016\/j.ghir.2013.04.002_bb0070","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ghir.2010.07.002","article-title":"Bioequivalence studies for three formulations of a recombinant human growth hormone: challenges and lessons learned","volume":"20","author":"Dao","year":"2010","journal-title":"Growth Hormon. IGF Res."},{"issue":"2","key":"10.1016\/j.ghir.2013.04.002_bb0075","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/(SICI)1520-6017(200002)89:2<168::AID-JPS4>3.0.CO;2-Q","article-title":"Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection","volume":"89","author":"Charman","year":"2000","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ghir.2013.04.002_bb0080","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1124\/dmd.111.043604","article-title":"Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs","volume":"40","author":"Wang","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ghir.2013.04.002_bb0085","series-title":"American Association of Pharmaceutical Scientists Annual Meeting","first-page":"T3355","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of circulating IGF-1 suppression produced by subcutaneous pegvisomant in healthy subjects","author":"Yin","year":"2006"}],"container-title":["Growth Hormone &amp; IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637413000385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637413000385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:47:22Z","timestamp":1761086842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637413000385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S1096637413000385"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2013.04.002","relation":{},"ISSN":["1096-6374"],"issn-type":[{"type":"print","value":"1096-6374"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegvisomant bioavailability of single 30mg\/mL subcutaneous injection compared to two 15mg\/mL subcutaneous injections: A pharmacokinetic, safety and tolerability study","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2013.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}